Sign In  |  Register  |  About San Rafael  |  Contact Us

San Rafael, CA
September 01, 2020 1:37pm
7-Day Forecast | Traffic
  • Search Hotels in San Rafael

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Week in Review: Broncus Stages $200 Million Hong Kong IPO for Pulmonary Devices

Deals and Financings   Broncus Holding, a  Hangzhou  pulmonary medical device company, completed a $200 million IPO in  Hong Kong  at a $1.3 billion valuation; Impact Therapeutics of Nanjing formed a collaboration with Toronto 's Cyclia to validate its novel oncology candidates using Cyclia's data based platform;  COVID-19 Pandemic   Clover, a  Chengdu  company, reported its adjuvanted protein-based COVID-19 vaccine candidate was 100% effective against serious COVID-19 disease in a pivotal global Phase II/II trial;  Trials and Approvals   Akeso reported an NDA for its PD-1/CTLA-4 bi-specific antibody has been accepted for review in  China  for cervical cancer; Suzhou CStone Pharma and US-based EQRx reported their partnered PD-(L)1 antibody doubled PFS in a Phase III trial among NSCLC patients;   Shanghai Hutchmed is starting a Phase III trial of its surufatinib and Junshi's PD-1 in patients with advanced neuroendocrine carcinoma; HighTide Therapeutics, a Shenzhen-Maryland biopharma, published positive data from a US Phase II trial of its novel treatment for NASH and type 2 diabetes; Shanghai CARsgen reported positive data from a China investigator-led trial of its Claudin18.2 CAR-T therapy for digestive system tumors; Beijing InnoCare and  Chengdu 's Keymed announced their  IND  for a CD20xCD3 bispecific antibody was cleared to start China trials in B-cell malignancies.  Stock Symbols: (HK: 2216) (HK: 9926) (HK: 2616) (NSDQ/AIM: HCM; HK: 13) (HK: 2171) (HK: 09969) (HK: 02162)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 SanRafael.com & California Media Partners, LLC. All rights reserved.